Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities
2020 · Pharmacology & Therapeutics · 56 citations
https://doi.org/10.1016/j.pharmthera.2020.107628
J
James Jiqi Wang
Tongji Hospital(CN)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
17
Papers
192
Citations
8
h-index
6
i10-index
James Jiqi Wang is an academic researcher from Tongji Hospital. The author has contributed to research in topics: Receptor Mechanisms and Signaling & COVID-19 Clinical Research Studies & Aortic Disease and Treatment Approaches. The author has an h-index of 8, co-authored 15 publications.
ORCID: 0000-0002-8878-668XPapers by this author
worksSpatiotemporal transcriptomics elucidates the pathogenesis of fulminant viral myocarditis
2025 · Signal Transduction and Targeted Therapy · 22 citations
https://doi.org/10.1038/s41392-025-02143-9
Molecular mechanisms of urate transport by the native human URAT1 and its inhibition by anti-gout drugs
2025 · Cell Discovery · 10 citations
https://doi.org/10.1038/s41421-025-00779-z
The coexistence of a novel WNK1 variant and a copy number variation causes hereditary sensory and autonomic neuropathy type IIA
2019 · BMC Medical Genetics · 5 citations
https://doi.org/10.1186/s12881-019-0828-5
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat